Eli Lilly & Co.'s CEO Discusses Q4 2011 Results - Earnings Call Transcript

Eli Lilly & Co. (LLY)

Q4 2011 Earnings Call

January 31, 2012 9:00 am ET

Executives

Ronika Pletcher -

Ilissa Rassner -

Derica W. Rice - Chief Financial Officer, Executive Vice President of Global Services and Member of Policy & Strategy Committee

Philip Johnson -

Jan M. Lundberg - Executive Vice President of Science & Technology and President of Lilly Research Laboratories

John C. Lechleiter - Chairman, Chief Executive Officer and President

Jeffrey N. Simmons - Senior Vice President and Head of Elanco Animal Health Business Unit

Analysts

Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division

Jami Rubin - Goldman Sachs Group Inc., Research Division

Marc Goodman - UBS Investment Bank, Research Division

Gregory B. Gilbert - BofA Merrill Lynch, Research Division

David Risinger - Morgan Stanley, Research Division

Steve Scala - Cowen and Company, LLC, Research Division

John T. Boris - Citigroup Inc, Research Division

Charles Anthony Butler - Barclays Capital, Research Division

Seamus Fernandez - Leerink Swann LLC, Research Division

Jeffrey Holford - Jefferies & Company, Inc., Research Division

Christopher Schott - JP Morgan Chase & Co, Research Division

Catherine J. Arnold - Crédit Suisse AG, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Q4 earnings call. [Operator Instructions] And as a reminder, today's conference call is being recorded. I would now like to turn the conference over to Ronika Pletcher, Director of Investor Relations. Please go ahead.

Ronika Pletcher

Good morning. Thank you for taking the time to join us for Eli Lilly & Co.'s Fourth Quarter 2011 Earnings Conference Call. I'm Ronika Pletcher, Director of Investor Relations. Joining me are our Chairman and CEO, John Lechleiter; our Chief Financial Officer, Derica Rice; our President of Lilly Research Laboratories, Dr. Jan Lundberg; our President of Elanco Animal Health, Jeff Simmons; and Ilissa Rassner and Phil Johnson from Investor Relations.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief